Global biotech company SOTIO has licensed a technology from Max Planck Innovation and the Lead Discovery Center (LDC) that addresses a novel target in tumor metabolism.
Researchers at the Max Planck Institute for Biology of Ageing first developed the innovation, and scientists at LDC helped advance it into drug discovery. Under the new licensing agreement, LDC and its academic partners will collaborate with SOTIO to perform further lead optimization and identify corresponding biomarkers for the technology.
Once a preclinical candidate is identified, SOTIO will lead the preclinical and clinical development, marketing, and commercialization of the drug. The company may provide research funding to LDC, as well as milestone payments and royalties on net sales of the drug. Any revenues that LDC receives will be shared with the inventors, the Max Planck Institute for Biology and Ageing, and the Max Planck Society.
“We are excited to collaborate with SOTIO,” says CEO of LDC Bert Klebl. “The team at SOTIO combines strong, global development expertise with the dynamic spirit of a mid-sized innovation leader. This makes them an ideal partner for translating the results of our collaborative efforts with the Max Planck team into novel therapies.
“Together,” adds Klebl, “we have investigated and developed a completely new molecular mechanism for the potential future therapy of cancer patients. With SOTIO on board, we are perfectly positioned to progress this new drug candidate to patients as fast as possible.”
Ladislav Bartonicek, CEO of SOTIO, comments, “Targeting cancer metabolism is a highly attractive and innovative approach for the treatment of cancer. Based on the world-class research at Max Planck, the team at LDC has generated very interesting lead candidates on this first-in-class cancer metabolism program with a promising safety and efficacy profile. We very much look forward to our collaboration with Max Planck and the LDC.”
Source: EIN News